“The incidence of very rare thromboembolic events was far lower – in AstraZeneca’s Vaxzevria vaccines and mRNA vaccines, such as Pfizer – compared to people diagnosed with Covid-19 infection.”
So in an AstraZeneca note, citing an extensive real-world study. The data was published as a pre-press on The Lancet server, surveyed over a million people and assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS ) following vaccination with an mRNA or Vaxzevria vaccine.
Covid, half of the hospitalized have complications. At any age
by Noemi Penna
“This real-world study offers further evidence of the favorable advantage: risk profile of Vaxzeria and demonstrates the critical role that all Covid-19 vaccines are playing in the fight against the pandemic,” explains Sir Mene Pangalos, Executive Vice President and BioPharmaceuticals R&D of the Anglo-Swedish multinational.
The analysis included 945,941 mRNA participants (778,534 with two doses), 426,272 participants in Vaxzevria, conducted between December 27, 2020 and May 19, 2021. The sample also included 222,710 Covid-19 participants identified between September 1, 2020 and March 1, 2021 and 4,570,149 background participants on January 1, 2017 from a public health database held in Catalonia, Spain.
The results are in line with recent reports from the Medicines and Healthcare Products Regulatory Agency (MHRA) Yellow Card Report, the UK system for collecting and monitoring information on safety issues, which also shows low rates of TTS after a second dose .
Covid: “Cause of thrombosis found with AstraZeneca and J&J vaccines”
by Irma D’Aria
No specific risk factors or definitive cause for TTS have been identified following Covid-19 vaccination, and AstraZeneca continues to carry out and support ongoing investigations into potential mechanisms. Additionally, these very rare events can be managed when symptoms are identified and treated appropriately.
The data were compared with predicted rates in a general population and in people with Covid-19. The safety profiles of Vaxzevria and the mRNA-based vaccine were similar and overall favorable. Very rare bleeding disorders (TTS) were observed with both vaccines, but these were in line with what would be expected in the general population and lower than those diagnosed with Covid.
Follow-up time was not sufficient to report rates after two doses of Vaxzevria, although other studies have shown that rates of rare blood clotting events are lower after a second dose.
Vaccine thrombosis: “This is how my life-saving treatment works to stop them”
by Giuliano Aluffi
Regardless of the vaccine used, the increase in thrombosis rates among people infected with Covid-19 was far greater than among those vaccinated. Venous thromboembolism rates were eight times higher after a diagnosis of Covid infection than the expected rate.
.